Glaukos (GKOS) Q1 2025: iDose-TR Drives 41% U.S. Glaucoma Growth, Offsetting Stent Declines
Glaukos’ Q1 performance underscores a pivotal shift as the iDose-TR launch powers robust U.S. glaucoma growth, counterbalancing stent headwinds and regulatory turbulence. Management modestly raised iDose expectations for the year, signaling confidence in adoption ramp and payer progress, while reaffirming full-year guidance amid macro caution. Investors should focus on the evolving mix between legacy and next-gen interventional glaucoma therapies as reimbursement and physician behavior reshape the competitive landscape.
Summary
- iDose-TR Accelerates Franchise Shift: Record U.S. glaucoma growth highlights iDose-TR’s rapid adoption as stents decline.
- Reimbursement Progress Unlocks Volume: Expanded MAC and commercial payer coverage is supporting a faster iDose-TR ramp.
- Full-Year Outlook Steady Amid Macro Caution: Management holds guidance, balancing Q1 upside with economic and competitive risks.
Performance Analysis
Glaukos reported record consolidated net sales, driven by a 41% year-over-year surge in U.S. glaucoma revenue, primarily from iDose-TR adoption. The U.S. glaucoma franchise reached $59.1 million in sales, while international glaucoma grew 15% as the company scaled its global commercial infrastructure. However, legacy U.S. stent revenue saw a mid-single-digit decline, reflecting the impact of new Medicare Administrative Contractor (MAC) Local Coverage Determinations (LCDs) that restrict the use of multiple MIGS (minimally invasive glaucoma surgery) devices in combination procedures.
Corneal health revenue remained subdued due to ongoing effects from the Medicare Drug Rebate Program (MDRP), with flat to low single-digit growth expected until the anticipated 2026 launch of Epioxa. Importantly, iDose-TR’s momentum is offsetting these headwinds, supporting the company’s decision to reaffirm full-year sales guidance of $475 to $485 million. Cash and equivalents exceeded $303 million, with no debt, providing ample flexibility for pipeline investment and business development.
- U.S. Franchise Mix Shifts: iDose-TR now drives the majority of U.S. glaucoma growth as stent volumes fall.
- International Execution Remains Robust: High single-digit to low double-digit growth expected despite emerging competitive trialing.
- Corneal Health Pipeline Progress: Epioxa NDA accepted by FDA, with a PDUFA date set for October 2025.
Overall, the quarter marks a clear inflection as next-generation therapies begin to define Glaukos’ growth trajectory, even as legacy segments face regulatory and market pressure.
Executive Commentary
"Our first quarter record results reflect the sustained growth acceleration in our business with strong performance driven by IDOS TR adoption and both our US and international glaucoma franchises overall."
Tom Burns, Chairman and CEO
"When you put all that together... it's going to imply that we actually are modestly increasing our I-dose expectations for the remainder of 2025 versus what you probably had or most people had in their models coming into the call."
Joe Gilliam, President and COO
Strategic Positioning
1. iDose-TR: Redefining Glaucoma Therapy
iDose-TR, an intracameral sustained-release drug implant, is rapidly establishing a new therapeutic category in glaucoma management. The product’s ability to deliver continuous therapy for up to three years is resonating with both physicians and patients, as evidenced by strong clinical feedback and expanding adoption. Glaukos’ launch strategy focuses on surgeon training, payer engagement, and building a robust clinical evidence base to cement iDose-TR as standard of care.
2. Navigating Regulatory Headwinds in Legacy Devices
New LCD restrictions by MACs have materially reduced the addressable market for stent-based MIGS in combination cataract procedures. Management anticipates a 10% to 15% reduction in MIGS volume for 2025, and now expects U.S. stent revenue to decline mid-single digits for the year. However, standalone stent use and the shift toward interventional glaucoma (IG) provide partial offsets, with Glaukos investing in clinical trials to generate evidence for future LCD revisions.
3. Pipeline and Portfolio Diversification
Glaukos is advancing a broad pipeline spanning corneal health (Epioxa), microshunt devices (PreserFlo), and next-gen retinal therapies (GLK401). The Epioxa NDA acceptance marks a key milestone, with commercial launch preparations underway for 2026. Meanwhile, the company’s balance sheet supports continued investment in both organic R&D and targeted business development, such as the expanded RadiusXR and TopCon Healthcare collaborations.
4. Payer and Market Access Expansion
Progress with Medicare MACs and growing commercial coverage is unlocking iDose-TR volume. Management reports that more than 50% of potential commercial and Medicare Advantage lives now have coverage, with the rest showing policy silence rather than denials. The company is methodically rolling out access to ensure positive physician and patient experiences, including plans for a $0 copay program to minimize out-of-pocket barriers.
5. Global Scale and Tariff Resilience
International glaucoma growth remains robust, with Glaukos scaling infrastructure ahead of anticipated new product approvals. Minimal direct exposure to U.S.-China tariffs, due to domestic manufacturing and sourcing, provides supply chain stability relative to peers.
Key Considerations
This quarter’s results mark a turning point in Glaukos’ business mix and strategic priorities, with iDose-TR’s ramp and payer progress offsetting regulatory and legacy product headwinds.
Key Considerations:
- iDose-TR Adoption Pace: Month-to-month growth and payer adjudication are critical to achieving implied H2 ramp in guidance.
- Stent Franchise Durability: Ongoing LCD restrictions will continue to weigh on legacy stent revenue, with only partial offset from standalone procedures.
- Pipeline Execution Risk: Timely FDA review and successful Epioxa launch in 2026 are pivotal for corneal health growth.
- Commercial and Medicare Advantage Access: Methodical rollout is prudent, but broad payer coverage is not yet universal, leaving some exposure to reimbursement delays.
- Macro and Competitive Pressures: Management’s decision to hold guidance reflects caution around macroeconomic uncertainty and new competitive product trialing internationally.
Risks
Exposure to regulatory changes remains acute, especially as LCD restrictions persist and new competitors trial products in key international markets. Macro uncertainty could dampen procedure volumes, and pipeline execution (notably Epioxa and iDose-T-Rex) is critical for future growth. Reimbursement progress, while positive, is not fully locked in, leaving some risk of delayed or uneven adoption.
Forward Outlook
For Q2 2025, Glaukos expects:
- Revenue contribution to represent 23% to 24% of full-year guidance, reflecting typical ophthalmology seasonality and iDose-TR launch dynamics.
- Continued sequential growth in iDose-TR, with broader MAC and commercial coverage supporting the ramp.
For full-year 2025, management reaffirmed guidance:
- Net sales of $475 to $485 million.
Management highlighted the following factors:
- iDose-TR adoption and payer progress as key drivers of second-half growth acceleration.
- Ongoing headwinds in legacy stents and corneal health, balanced by pipeline progress and capital discipline.
Takeaways
Glaukos is successfully navigating a franchise transition, with next-gen therapies offsetting legacy pressures and positioning the company for long-term growth.
- Product Mix Transformation: iDose-TR is now the growth engine, while stents face structural headwinds from regulatory changes and market evolution.
- Guidance Reflects Balanced Optimism: Management’s modest iDose-TR raise and steady full-year outlook signal confidence in payer and physician adoption, tempered by macro caution.
- Pipeline and Access Remain Critical: Investors should watch for Epioxa milestones, continued MAC/commercial payer expansion, and evidence generation to support future regulatory and reimbursement wins.
Conclusion
Glaukos’ Q1 confirms a strategic pivot toward innovative, long-duration glaucoma therapies, with iDose-TR’s ramp providing a new foundation for growth. While legacy segments face ongoing pressure, the company’s execution on payer access, clinical adoption, and pipeline advancement will determine its ability to sustain momentum and capture long-term market leadership.
Industry Read-Through
Glaukos’ results offer a clear signal for the ophthalmology sector: next-generation, procedure-based drug delivery is gaining traction as payers and physicians seek alternatives to chronic drop therapy and device-based MIGS. The regulatory landscape remains a key determinant of competitive positioning, as LCD restrictions reshape legacy device economics. Companies with robust payer engagement, strong clinical evidence, and diversified pipelines are best positioned to weather macro and reimbursement shocks. The methodical approach to commercial rollout and copay support also highlights the growing importance of access programs in specialty pharma and device markets.